$LLY

Jonsson Patrik sold $7.6M of LLY

Jonsson Patrik (EVP & President, LLY Int'l) sold 6,500 shares of ELI LILLY & Co (LLY) at $1175.10 ($7.64M total) on 2026-08-17 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Jonsson Patrik
Published Aug 18, 2026, 8:20 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 18, 2026, 8:50 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$LLY
Neutral
high confidence
Mentioned
$LLY
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LLYNeutralLow
01

Why it matters

The only new information is the specific sale size, price, and post-transaction holdings; it does not include guidance, trial results, regulatory actions, or deal terms.

02

Market read

Traders may note insider selling, but the 10b5-1 framing and lack of fundamental updates make it low-signal for price action.

03

What to watch

The disclosure does not indicate whether sales were part of broader diversification, tax planning, or option exercises, limiting inference beyond the fact of selling.

Relevance 5/10Novelty 3/10Timing: filed 2026-08-18, transaction dated 2026-08-17

Background

The article is an SEC Form 4 insider transaction disclosure for Eli Lilly & Co.

Company-level read

Ticker impact

$LLYNeutralHigh confidence
Context

SEC Form 4 shows EVP and President Jonsson sold 6,500 shares at $1,175.10 on 2026-08-17 under a 10b5-1 plan.

Expected impact

Likely minimal immediate price impact; any effect is more sentiment-driven than fundamental.

Evidence & confidence

The filing is an open-market sale by an insider, explicitly tied to a pre-arranged 10b5-1 plan, and provides no new company-specific operational or financial information.

Market effects

No direct sector read-through; this is company-specific insider trading disclosure.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, unusually large or clustered insider selling can be interpreted as private caution, though this article provides no comparative context.

Key entities

  • ELI LILLY & Co

    Subject of the Form 4 insider sale by EVP and President, LLY International, Patrik Jonsson.

  • Patrik Jonsson

    EVP and President, LLY International, reported an open-market sale under a pre-arranged 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$BMYMedAI 8/10

Bristol-Myers Squibb (BMY) Bets $2.3 Billion on Texas While Eli Lilly (LLY) Wins in the UK

Bristol-Myers Squibb (BMY) will invest $2.3B in a Houston plant, part of a $40B U.S. investment. Eli Lilly (LLY) won UK approval for its weight-loss drug, Foundayo. BMY's investment aims to boost domestic manufacturing, while LLY expands internationally. Both companies face challenges, including patent expirations for BMY and market competition for LLY. Hedge funds show mixed interest in both stocks.

$BMYMedAI 8/10

Pharmaceuticals Stocks Q2 Highlights: Ocular Therapeutix (NASDAQ:OCUL)

Bristol-Myers Squibb (BMY) reported Q2 revenues of $12.97B, up 5.7% YoY, beating estimates. Zoetis (ZTS) reported flat revenues of $2.47B, missing estimates. Amphastar (AMPH) reported $183.9M in revenues, up 5.4% YoY, beating estimates. Eli Lilly (LLY) reported $22.97B in revenues, up 47.7% YoY, beating estimates. Market sentiment has shifted from AI to geopolitics.

$LLYHighAI 9/10

Why big pharma wants in on the psychedelics business

Eli Lilly acquired AtaiBeckley for $2.8B to advance psychedelic drugs for mental health. The Trump administration supports research, aiming to fast-track approvals. Psychedelics, like psilocybin and MDMA, are being studied for treatment-resistant disorders. Publicly traded companies, including Definium Therapeutics and Compass Pathways, are developing these drugs, with potential FDA decisions this year.